Berger et al.33 reported that despite a substantial decrease in PTSD and comorbid depressive symptoms over the course of an open-label trial of escitalopram monotherapy, they detected no significant changes in serum BDNF levels throughout the 12-week therapy period. This evidence concerns the gene BDNF and post-traumatic stress disorder.